Compare GSK plc (GSK) vs Tilray Brands Inc (TLRY) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

TLRY trades at $4.355, down 0.57% on the day, amid a bearish technical signal and weak earnings performance. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, while revenue grew to $821.31 million. Recent news includes medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.

The outlook remains challenging due to persistent losses and high debt levels, though low valuation ratios like P/S of 0.55 and P/B of 0.35 may attract value investors. Key risks include profitability struggles, regulatory uncertainty, and competitive pressures in the cannabis sector. Analyst sentiment is mixed, with 65% hold ratings reflecting caution.